The present invention relates to antibodies (and fragments variants fusions and derivatives thereof) with multivalent binding specificity for CD40 which have a potency for dendritic cell activation which is higher than or is equal to the potency for B cell activation and wherein the antibody antigen binding fragment or fusion variant or derivative thereof has an affinity (KD) for CD40 of less than 1x10 M which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions uses methods and kits comprising such antibodies.
